Skip to content
Teethgrinder – Lifestyle
Author:
Acurx Pharmaceuticals, Inc.
Acurx Announces New Ibezapolstat Clinical Trial Program in Patients with Recurrent CDI That Has the Potential to Shift the Paradigm of Treatment and Prevention of C. difficile Infection
March 9, 2026